Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

dasatinib

Known as: BMS dasatinib, Dasatinib [Chemical/Ingredient], N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide 
An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth… Expand
National Institutes of Health

Related topics

Related topics

25 relations

Broader (2)

Antineoplastic AgentsProtein Kinase Inhibitors

Narrower (3)

BMS 354825Spryceldasatinib anhydrous
CSK protein, humanEphrin Type-A Receptor 2, humanFusion Proteins, bcr-ablIn Blood
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Treatment‐free remission with first‐ and second‐generation tyrosine kinase inhibitors
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase… Expand
Review
2018
Review
2018
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling…
BACKGROUND The present review is part of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study… Expand
  • table 1
  • table 2
Review
2018
Review
2018
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm, the incidence of which increases with age. Tyrosine kinase… Expand
  • table 1
  • table 3
Review
2018
Review
2018
Advances and Challenges on Management of Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) originate from interstitial cells of Cajal and account for over 5,000 newly diagnosed… Expand
Highly Cited
2011
Highly Cited
2011
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.
Triple-negative breast cancer (TNBC) is a highly diverse group of cancers, and subtyping is necessary to better identify… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Highly Cited
2010
Highly Cited
2010
Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
 
Highly Cited
2007
Highly Cited
2007
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
The BCR-ABL tyrosine kinase inhibitor imatinib represents the current frontline therapy in chronic myeloid leukemia. Because many… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Highly Cited
2007
Highly Cited
2007
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Although imatinib induces marked responses in patients with chronic myeloid leukemia (CML), resistance is increasingly… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Highly Cited
2006
Highly Cited
2006
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
BACKGROUND The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive… Expand
  • table 1
  • table 2
  • table 2
  • table 3
  • figure 1
Highly Cited
2006
Highly Cited
2006
Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.
Dasatinib (BMS-354825), a novel dual SRC/BCR-ABL kinase inhibitor, exhibits greater potency than imatinib mesylate (IM) and… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE